Marsh Barbel — Benefits Deep Dive

The parent page for Hygrophila auriculata is unusually candid: it says outright that the human evidence is essentially nonexistent, and a live re-check for this leg confirms that verdict rather than overturning it — across all four taxonomic names this plant has published under (Hygrophila auriculata, Hygrophila spinosa, Asteracantha longifolia, and the eighteenth-century placement Barleria longifolia), PubMed's own Clinical Trial and Randomised Controlled Trial publication-type filters return zero records, run today. So this leg is not a correction of the parent page. It is the second layer down: what does the underlying animal literature actually contain, herb by herb of it, once you stop counting papers and start reading them.

That reading turned up two things worth flagging before anything else. First, one of the most-cited papers in this exact space — a 2021 Environmental Research study claiming both liver protection and antibacterial activity for this plant — was retracted in 2025, after an Expression of Concern in February of that year. It does not appear anywhere in this leg's citation lists, and if you find it quoted elsewhere, that quotation is now citing a retracted paper. Second, a similarly-cited 2016 Food Chemistry paper on Kombucha-fermented herbal teas, which included this plant among ten tested species, was also retracted — the same year it was published. Two retractions out of a total pool of only 57 indexed records across all four names is a strikingly high rate, and it is one more reason to treat this plant's literature as something to check paper-by-paper rather than to cite by search-result count.

Once the retracted material is set aside, four real claim areas remain, and they are not equally strong. The liver-protection literature is the most internally consistent: eight independent Indian research groups, working between 1996 and 2010, converged on broadly the same finding using broadly the same toxin-challenge design. The flagship traditional claim — that this is a diuretic — turns out to rest on a single retrievable primary paper from 1967, with no confirmable modern replication and no confirmable furosemide comparison despite that claim circulating informally. The male-reproductive claim is more substantial than its usual "aphrodisiac" framing suggests, but the last decade of it has quietly become a different claim — protecting against a specific antiandrogen drug's damage, not boosting normal function — and that distinction matters. And the newest publications, the ones that make this plant look like an active current research subject, are mostly nanoparticle-synthesis and computational-biology papers that use the plant as a chemical source rather than testing any of its traditional uses at all.

Deep-Dive Articles

Back to Table of Contents

Table of Contents

1. Deep-Dive Articles
2. Evidence Ledger for the Whole Leg
3. Four Ways This Evidence Gets Overstated
4. Key Research: Liver and Jaundice
5. Key Research: Diuretic Tradition and Kidney Stones
6. Key Research: Male Reproductive Claims
7. Key Research: Anti-Inflammatory and Blood-Sugar
8. External Authoritative Resources
9. Connections

Evidence Ledger for the Whole Leg

Ranked by the strength of the evidence, not by how confidently a product label states the claim.

1. Rodent hepatoprotection against chemical liver toxins. Tier: consistent across eight independent groups, prevention-design animal studies only. The plant's best-supported activity by volume and by independent replication — and still zero human data.
2. Protection against antiandrogen-drug-induced testicular dysfunction. Tier: consistent across four studies by two research groups, 2011–2023, single species, real hormonal and histological endpoints in the more recent work. A narrower and more interesting claim than "aphrodisiac," and the strongest human-relevant mechanistic story in this entire leg despite having zero human trials of its own.
3. Anti-inflammatory activity of isolated compounds and fractions. Tier: three real primary studies, 2016–2025, rodent oedema and septic-shock models plus one isolated-compound study with a drug comparator. Genuine pharmacology; the compounds involved are not unique to this species.
4. Prevention of mineral deposition in a chemically induced kidney-stone model. Tier: one real rat study. Prevents new deposits when co-administered with the stone-forming agent; does not test, and cannot be extended to, dissolving a stone that already exists.
5. The traditional diuretic claim itself. Tier: old, weak and positive — distinct from both absent and refuted. One retrievable primary paper, from 1967, no confirmable modern replication and no confirmable furosemide-comparison study despite that comparison circulating in secondary sources.
6. Antihyperglycaemic / blood-sugar-lowering activity. Tier: thin and structurally confounded. One genuine single-species rat study (2006); one 2024 study that tested the claim mainly as a two-plant flower-powder combination; two 2026 papers that are computational network-pharmacology analyses, one of which adds real in-vitro enzyme-inhibition data for an isolated compound that is not unique to this plant.
7. Anaemia relief via the Bengali kulekhara leaf tradition. Tier: covered on the parent page — rodent haematinic data plus the much more parsimonious explanation that a daily bowl of iron- and folate-containing greens improves diet-driven anaemia regardless of species. Not re-litigated in this leg.
8. Human clinical trials, any indication. Tier: absent, confirmed by publication-type filter. Not "we could not find one" — PubMed's own Clinical Trial and Randomised Controlled Trial filters, queried live across all four species names, return zero records.
9. The three most solid facts in this entire leg are all limitations: no dose has ever been established in a human trial of any kind; no pharmacokinetic study exists for any named constituent; and two of the papers most likely to surface in a casual search of this plant's pharmacology are retracted.

Four Ways This Evidence Gets Overstated

Labelled at the point of use throughout the four deep-dive pages, and collected here because the same four patterns recur across all of them.

1. Retraction, not just weakness. Two papers in this plant's small literature — a 2021 hepato/nephroprotective study and a 2016 Kombucha-fermentation antioxidant study — were formally retracted. Retraction is a stronger signal than "low quality": it means the journal itself withdrew the finding, usually for reasons well beyond small sample size. Neither appears in any citation list on this leg, and both are named explicitly in the relevant deep-dive so a reader who encounters them elsewhere recognises them.
2. Part and formula substitution in the newest work. The only 2024 antihyperglycaemic study used dried flower powder — not the seed, root, leaf or whole-plant preparations every traditional and older pharmacological source uses — and tested it mainly as a combination with a second plant, Cordia macleodii. A positive result for a two-plant flower-powder mixture is evidence about that mixture, not about the seeds someone buys as talmakhana.
3. Compound-not-unique-to-species. Three separate mechanistic threads in this leg — lupeol (already flagged on the parent page), a beta-sitosterol glucoside credited with anti-inflammatory activity, and 13-docosenamide credited with blood-sugar activity — are all compounds found across many unrelated plants, and the last is also a common industrial plastics slip-agent. None of the three is evidence that this species specifically, rather than the compound class generically, is doing the work.
4. Preclinical design read as if it were clinical. Almost every animal study in this leg is a prevention design (extract given before or alongside the toxin or insult, not after an established problem) and every positive-control comparison (to furosemide, indomethacin, or a reference drug) validates that the rodent assay is working rather than ranking the herb against the drug. Both distinctions are named at the point they matter in each deep-dive rather than once here.

Key Research: Liver and Jaundice

The full citation list, with methods notes, is on the Liver and Jaundice deep-dive. Highlights:

1. Hewawasam RP, Jayatilaka KAPW, Pathirana C, Mudduwa LK. Protective effect of Asteracantha longifolia extract in mouse liver injury induced by carbon tetrachloride and paracetamol. Journal of Pharmacy and Pharmacology, 2003. Find on PubMed.
2. Shanmugasundaram P, Venkataraman S. Hepatoprotective and antioxidant effects of Hygrophila auriculata root extract. Journal of Ethnopharmacology, 2006. Find on PubMed.
3. Raj VP, Chandrasekhar RH, and colleagues. In vitro and in vivo hepatoprotective effects of the total alkaloid fraction of Hygrophila auriculata leaves. Indian Journal of Pharmacology, 2010. Find on PubMed.
4. Ahmed S, Rahman A, Mathur M, Athar M. Anti-tumor promoting activity of Asteracantha longifolia against experimental hepatocarcinogenesis in rats. Food and Chemical Toxicology, 2001. Find on PubMed.
5. Retracted — excluded, named for recognition only. Narayanan M, Gopi A, and colleagues. Hepato and nephroprotective activity of methanol extract of Hygrophila spinosa and its antibacterial potential against multidrug-resistant Pandoraea sputorum. Environmental Research, 2021, retracted 2025. Verify the retraction on PubMed.

Key Research: Diuretic Tradition and Kidney Stones

The full citation list is on the Diuretic Tradition and Kidney Stones deep-dive. Highlights:

1. Kumari GS, Iyer GY. Preliminary studies on the diuretic effects of Hygrophila spinosa and Tribulus terrestris. Indian Journal of Medical Research, 1967. The sole retrievable primary diuretic study. Find on PubMed.
2. Ingale KG, Thakurdesai PA, Vyawahare NS. Effect of Hygrophila spinosa in ethylene glycol induced nephrolithiasis in rats. Indian Journal of Pharmacology, 2012. Find on PubMed.
3. Ingale KG, Thakurdesai PA, Vyawahare NS. Protective effect of Hygrophila spinosa against cisplatin induced nephrotoxicity in rats. Indian Journal of Pharmacology, 2013. Find on PubMed.
4. Bennett WM. Drug interactions and consequences of sodium restriction. American Journal of Clinical Nutrition, 1997. General nephrology background explaining the lithium caution mechanistically. Find on PubMed.

Key Research: Male Reproductive Claims

The full citation list is on the Male Reproductive and Vrishya Claims deep-dive. Highlights:

1. Vyas NY, Raval MA. Aphrodisiac and spermatogenic potential of alkaloidal fraction of Hygrophila spinosa T. Ander in rats. Journal of Ethnopharmacology, 2016. Find on PubMed.
2. Ghosh C, Mallick C. Protective effect of ethanolic extract of Hygrophila auriculata seeds in cyproterone acetate–induced sexual dysfunction in male albino rats. Andrologia, 2020. Find on PubMed.
3. Ghosh C, Maity R, Roy A, Mallick C. Dose-dependent protective effect of Hygrophila auriculata seeds on cyproterone acetate–induced testicular dysfunction. Reproductive Sciences, 2023. Find on PubMed.
4. Detection of undeclared erectile-dysfunction drugs and analogues in dietary supplements by ion mobility spectrometry. Analytical chemistry background for the adulteration caution. Find on PubMed.

Key Research: Anti-Inflammatory and Blood-Sugar

The full citation list is on the Anti-Inflammatory and Blood-Sugar deep-dive. Highlights:

1. Hussain MS, Azam F, Ahamed KF, Ravichandiran V, Alkskas I. Anti-endotoxin effects of terpenoids fraction from Hygrophila auriculata in lipopolysaccharide-induced septic shock in rats. Pharmaceutical Biology, 2016. Find on PubMed.
2. Alghamdi MA, Azam F, and colleagues. Isolation, characterization, and anti-inflammatory effects of β-sitosterol-β-D-glucoside from Hygrophila auriculata. Chemistry & Biodiversity, 2025. Find on PubMed.
3. Vijayakumar M, Govindarajan R, and colleagues. Action of Hygrophila auriculata against streptozotocin-induced oxidative stress. Journal of Ethnopharmacology, 2006. The one genuine single-species diabetes-model study in this literature. Find on PubMed.
4. Saravanan S, Arockiasamy E. Systems-level analysis of 13-docosenamide reveals its regulatory role on PPAR, AMPK, and insulin pathways in T2DM: in vitro and in silico approaches. Cell Biochemistry and Biophysics, 2026. Find on PubMed.
5. Retracted — excluded, named for recognition only. Watawana MI, Jayawardena N, and colleagues. Application of the Kombucha "tea fungus" for the enhancement of antioxidant and starch hydrolase inhibitory properties of ten herbal teas. Food Chemistry, 2016, retracted the same year. Verify the retraction on PubMed.

Back to Table of Contents

External Authoritative Resources

• NCCIH — the US National Center for Complementary and Integrative Health; how botanical evidence is graded.
• NIH Office of Dietary Supplements — fact sheets and label literacy for supplement ingredients.
• LiverTox — the NIH database of drug- and herb-induced liver injury, relevant to the hepatoprotection claim.
• FDA — Tainted Sexual Enhancement Products — the regulatory record behind the adulteration caution on the reproductive-claims page.
• PubMed — all three modern names at once — the search this entire leg was built from.

Back to Table of Contents

Connections

• All Herbs
• Marsh Barbel (Main Page)
• Liver and Jaundice Claims
• Diuretic Tradition and Kidney Stones
• Male Reproductive and Vrishya Claims
• Anti-Inflammatory and Blood-Sugar Research
• Milk Thistle — the liver herb with actual human trials, for comparison
• Uva Ursi — the urinary herb that does have some human data
• Horsetail — another traditional diuretic with a comparable evidence problem
• Saw Palmetto — the men's-health herb most studied in men
• Kidney Stones — what actually reduces recurrence
• Urinary Tract Infections — why these need antibiotics, not demulcents
• Diabetes — where the alpha-glucosidase mechanism is already a licensed drug class
• Potassium — the mineral behind both the diuretic mechanism and its main caution

Back to Table of Contents